Brokerages expect Orthopediatrics Corp (NASDAQ:KIDS) to post sales of $14.16 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Orthopediatrics’ earnings. The highest sales estimate is $14.20 million and the lowest is $14.10 million. The business is expected to announce its next quarterly earnings report on Monday, August 13th.

On average, analysts expect that Orthopediatrics will report full year sales of $55.46 million for the current year, with estimates ranging from $55.00 million to $55.70 million. For the next fiscal year, analysts forecast that the business will post sales of $67.02 million per share, with estimates ranging from $66.00 million to $67.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Orthopediatrics.

Orthopediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Monday, May 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.06. The company had revenue of $12.09 million for the quarter, compared to analyst estimates of $11.38 million.

KIDS has been the subject of several research analyst reports. BidaskClub upgraded shares of Orthopediatrics from a “sell” rating to a “hold” rating in a report on Thursday, April 19th. Zacks Investment Research upgraded Orthopediatrics from a “sell” rating to a “hold” rating in a report on Friday, May 18th. Piper Jaffray Companies increased their price objective on Orthopediatrics from $24.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, July 5th. William Blair restated an “outperform” rating on shares of Orthopediatrics in a report on Wednesday, June 27th. Finally, ValuEngine upgraded Orthopediatrics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Orthopediatrics presently has a consensus rating of “Buy” and a consensus price target of $25.67.

In other Orthopediatrics news, General Counsel Daniel J. Gerritzen sold 11,145 shares of the stock in a transaction dated Friday, April 13th. The stock was sold at an average price of $17.92, for a total transaction of $199,718.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David R. Bailey sold 30,231 shares of the stock in a transaction dated Friday, April 13th. The stock was sold at an average price of $17.92, for a total value of $541,739.52. The disclosure for this sale can be found here. Insiders sold 70,847 shares of company stock valued at $1,269,578 over the last 90 days. 46.10% of the stock is currently owned by company insiders.

A number of institutional investors have recently modified their holdings of the business. Teachers Advisors LLC acquired a new stake in Orthopediatrics during the 4th quarter worth about $102,000. TIAA CREF Investment Management LLC acquired a new stake in Orthopediatrics during the 4th quarter worth about $130,000. California State Teachers Retirement System acquired a new stake in Orthopediatrics during the 4th quarter worth about $141,000. Deutsche Bank AG acquired a new stake in Orthopediatrics during the 4th quarter worth about $196,000. Finally, Millennium Management LLC acquired a new stake in Orthopediatrics during the 1st quarter worth about $172,000. Hedge funds and other institutional investors own 35.35% of the company’s stock.

Shares of Orthopediatrics traded up $0.10, hitting $29.12, during trading on Friday, MarketBeat Ratings reports. 64,255 shares of the company were exchanged, compared to its average volume of 64,150. The company has a market capitalization of $371.67 million and a PE ratio of -5.11. The company has a debt-to-equity ratio of 0.57, a quick ratio of 4.16 and a current ratio of 6.24. Orthopediatrics has a 1-year low of $14.00 and a 1-year high of $31.39.

Orthopediatrics Company Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.

Get a free copy of the Zacks research report on Orthopediatrics (KIDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Orthopediatrics (NASDAQ:KIDS)

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.